Press release article from our research archive:

Pharmacyclics Announces Initiation of Single Agent Xcytrin Phase 2 Clinical Trial in Recurrent, Metastatic Non-Small Cell Lung Cancer.

SUNNYVALE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced that it has initiated an open-label Phase 2 clinical trial of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead cancer therapeutic candidate, as a second-line treatment for patients with recurrent, metastatic non-small cell lung cancer (NSCLC). The trial is planned to enroll 108 patients at 12 sites across the U.S. and Canada.

"The purpose of this trial is to evaluate the safety and efficacy of single agent Xcytrin in recurrent NSCLC," said Markus Renschler, M.D., vice president of Oncology Clinical Development at Pharmacyclics. "Xcytrin has shown promising activity in ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!